Group 1: Regulatory Developments - The National Healthcare Security Administration (NHSA) is soliciting public opinions on the "Guidelines for Real-World Comprehensive Value Assessment of Drugs" to establish a unified national evaluation system [1] - Huadong Medicine's subsidiary received FDA approval for clinical trials of DR10624, a novel drug targeting metabolic-associated fatty liver disease [1] - Fosun Pharma's subsidiary has had its drug registration application for erythromycin lactobionate injection accepted by the National Medical Products Administration [2] - Stone Pharmaceutical's new drug for hypertension has received FDA approval for clinical trials in the U.S. [3] - Zhi Mei Ru Kang's siRNA therapy for ALS has entered Phase 2 clinical trials [4] Group 2: Market and Corporate Developments - Cap Bio's major shareholders have increased their stake from 31.52% to 33.05% following capital changes and share buybacks [5] - Bluestar Medical's product is expected to be selected for national centralized procurement of drug-coated balloons, which could enhance its market presence [7] - NVIDIA and Eli Lilly have announced a $1 billion collaboration to establish an AI innovation lab focused on drug discovery and development [8] - Dr. Wang Qiang has transitioned from Xiansheng Pharmaceutical to Ganli Pharmaceutical as Senior Vice President and Chief Strategy Officer [9] Group 3: Quality Control and Safety - China Resources Double Crane has addressed recent quality issues with sodium bicarbonate injection products, clarifying that non-compliance was due to packaging issues during transport [10]

Group 1 - The company achieved a significant milestone by commercializing its CAR-T therapy, Zevokiorunsai (CT053), for the treatment of relapsed/refractory multiple myeloma (R/R MM), marking a successful transition from research to commercialization [1] - Zevokiorunsai received NMPA approval in February 2024, becoming one of the first BCMA-targeted CAR-T drugs approved in China, with a 71.6% sCR/CR rate among R/R MM patients [1] - The company has established a deep collaboration with East China Pharmaceutical, which has formed a dedicated commercialization team to promote Zevokiorunsai, with over 111 valid orders received [1] Group 2 - The company is advancing its pipeline in solid tumors with its core product, Shurujikiorunsai (CT041), targeting CLDN18.2 for gastric and gastroesophageal junction adenocarcinomas, which has entered the NDA stage [2] - CT041 demonstrated significant improvements in progression-free survival (mPFS) and overall survival (mOS) in clinical trials, particularly in patients with CLDN18.2 positive G/GEJC [3] Group 3 - The company is developing a universal CAR-T platform, THANK-u Plus, aimed at standardizing and scaling cell therapy production, with promising results in overcoming immune rejection issues [3] - CT0596, targeting BCMA, has received IND applications for clinical trials in R/R MM and primary plasma cell leukemia (pPCL), while CT1190B is in trials for R/R B-NHL [4] Group 4 - Preliminary results for CT0596 in R/R MM show a median follow-up of 4.14 months, with 6 out of 8 evaluable patients achieving at least partial response, and no severe adverse events reported [4] - The company has a pipeline for in vivo CAR-T therapies, demonstrating significant efficacy in mouse models for targeting CD19/CD20 [4] Group 5 - Revenue projections for the company are estimated at 118 million, 310 million, and 714 million yuan for 2025, 2026, and 2027 respectively, with net losses expected to decrease over the same period [4]

Group 1 - The stock price of Shangwei New Materials has significantly increased since July 2025, leading to abnormal trading fluctuations, and the company may apply for a trading suspension if the price continues to rise [1] - CITIC Securities reported a net profit of 30.05 billion yuan for 2025, a year-on-year increase of 38.46%, driven by growth in brokerage, investment banking, and proprietary trading [2] - Huibo Technology's controlling shareholder will change to Tianjin State-owned Assets Supervision and Administration Commission after transferring 341 million shares, representing 25.60% of the total share capital [3] Group 2 - Caixun Co. plans to issue convertible bonds to raise up to 1.46 billion yuan for projects including the construction of an intelligent computing center and AI application development [4] - Jinhaitong expects a net profit of 160 to 210 million yuan for 2025, a year-on-year increase of 103.87% to 167.58%, due to rising demand in the semiconductor packaging sector [5] - Aoyuan Ceiling announced that it may apply for a trading suspension if its stock price continues to rise significantly [6] Group 3 - Yanshan Technology's commercialization of brain-machine interface and brain-like intelligence business is still in the early stages, with no revenue generated yet [7] - Haige Communication expects a net loss for 2025 due to industry client adjustments and increased investment in innovative businesses [9] - Hu Silicon Industry anticipates a net loss of 1.28 to 1.53 billion yuan for 2025, with a significant increase in losses compared to the previous year [10] Group 4 - Guangyun Technology may apply for a trading suspension if its stock price continues to rise abnormally [11] - Wenkang Development plans to swap its main assets and liabilities with 100% equity of Wenkang Mining and Luzhong Mining, facilitating a business transformation [12] - Jinqiao Information clarified that its AI-related judicial business is not its main business and does not significantly impact overall performance [13] Group 5 - Yonghe Co. expects a net profit increase of 110.87% to 150.66% for 2025, while CITIC Bank anticipates a 2.98% increase in net profit to 70.62 billion yuan [14] - Guotou Power's power generation volume decreased by 8.12% year-on-year for 2025, while Jiamei Packaging expects a net profit decrease of 43% to 53% [14] - Shengke Communication anticipates a net loss of 120 to 160 million yuan for 2025 [14]

Core Viewpoint - East China Pharmaceutical announced that its subsidiary, Zhejiang Daor Biotechnology Co., Ltd. (referred to as "Daor Bio"), has received approval from the U.S. Food and Drug Administration (FDA) for a clinical trial application for the drug DR10624, which targets Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [1]. Company Summary - Daor Bio's clinical trial application for DR10624 has been approved by the FDA, allowing the company to conduct clinical trials in the United States [1]. - The drug is specifically aimed at treating MASLD, a condition related to metabolic dysfunction [1]. Industry Summary - The approval from the FDA signifies a potential advancement in the treatment options available for MASLD, which may impact the pharmaceutical industry focused on metabolic diseases [1]. - This development could enhance the competitive positioning of East China Pharmaceutical within the biopharmaceutical sector [1].

Core Viewpoint - East China Pharmaceutical (000963.SZ) announced that its subsidiary, Zhejiang Daor Biotechnology Co., Ltd. (referred to as "Daor Bio"), has received notification from the U.S. Food and Drug Administration (FDA) that its clinical trial application for the drug DR10624 injection has been approved, allowing clinical trials to be conducted in the U.S. for the indication of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [1] Group 1 - East China Pharmaceutical's subsidiary Daor Bio has received FDA approval for clinical trials of DR10624 injection [1] - The approved indication for the clinical trial is Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [1]

Group 1: Resumption of Trading - Unisplendour plans to acquire 100% equity of Ruineng Semiconductor from 14 parties through share issuance and cash payment, leading to stock resumption [1] - Minmetals Development's board approved major asset replacement proposals, resulting in stock resumption [2] - Huibo's actual controller will change to Tianjin State-owned Assets Supervision and Administration Commission, with stock resuming tomorrow [3] Group 2: Private Placement - Lante Optics intends to raise no more than 1.055 billion yuan for AR optical product industrialization, production capacity enhancement of glass aspheric lenses, micro-nano optical components R&D, and working capital [4] Group 3: Equity Transfer - Jinhai High-tech's controlling shareholder, Huitou Holdings, plans to transfer 5% of shares at a price of 12.72 yuan per share through an agreement [4] Group 4: External Investment and Daily Operations - Hongda Electronics' subsidiary plans to invest 1 billion yuan in Wuxi High-tech Development Zone for semiconductor special device chip research, design, production, and testing [5] - Caixun plans to issue convertible bonds to raise no more than 1.46 billion yuan for intelligent computing center construction, Rich AIBox platform R&D upgrades, and enterprise-level AI applications [5] - Dingtong Technology intends to issue convertible bonds to raise no more than 930 million yuan for company expansion, high-speed communication and liquid cooling production, new energy BMS production, and working capital [5] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of DR10624 injection [6] - Xizi Clean Energy reported a cumulative new order of 5.998 billion yuan for 2025 [7] - Tianli Lithium Energy's subsidiary is expected to reduce production by 1,500 to 2,000 tons due to maintenance [8] Group 5: Performance Changes - CITIC Securities expects a net profit of 30.051 billion yuan in 2025, a year-on-year increase of 38.46% [9] - Four-dimensional Map expects a net profit of 90.0925 million to 117 million yuan in 2025, turning profitable due to the booming market for automotive assisted driving [9] - Jinhai Tong expects a net profit of 160 million to 210 million yuan in 2025, a year-on-year increase of 103.87% to 167.58% due to growing demand in the semiconductor packaging and testing equipment sector [9] - Shanghai Silicon Industry anticipates a net loss of 1.53 billion to 1.28 billion yuan in 2025 [10] - Jiamei Packaging expects a net profit of 85.4371 million to 104 million yuan in 2025, a year-on-year decrease of 43.02% to 53.38% due to a "small year" in the beverage industry [10]

近日，华东医药股份有限公司（以下简称"公司"） 控股子公 司浙江道尔生物科技有限公司（以下简称"道尔生物"）收到美国食 品药品监督管理局（以下简称"美国 FDA"）通知，由道尔生物申 报的 DR10624 注射液药品临床试验申请已获得美国 FDA 批准，可在 美国开展临床试验，适应症为代谢相关脂肪性肝病（Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD）。现将有关 详情公告如下： 一、该药物基本信息 证券代码：000963 证券简称：华东医药 公告编号：2026-002 华东医药股份有限公司 关于控股子公司获得美国FDA新药临床试验批准通知的公 告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 药物名称：DR10624 注射液 IND 编号：180034 适应症：代谢相关脂肪性肝病（Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD） 申请事项：临床试验 DR10624 是道尔生物自主研发的全球首创（Fir ...

Core Viewpoint - The company has received FDA approval for a clinical trial of its drug DR10624, aimed at treating metabolic-associated fatty liver disease [1] Group 1 - The company's subsidiary, Zhejiang Daor Biotechnology Co., Ltd., is responsible for the drug application [1] - The FDA notification indicates that the clinical trial can now proceed in the United States [1] - The approved indication for the drug is metabolic-associated fatty liver disease [1]

Core Viewpoint - The announcement highlights that Zhejiang Daer Biotechnology, a subsidiary of Huadong Medicine, has received FDA approval for the clinical trial application of the drug DR10624, aimed at treating Metabolic Associated Steatotic Liver Disease (MASLD) [1] Group 1 - The drug DR10624 is a globally innovative long-acting tri-specific agonist targeting FGF21R, GCGR, and GLP-1R, developed independently by Daer Biotechnology [1] - DR10624 has successfully completed Phase II clinical trials for severe hypertriglyceridemia, achieving positive top-line results [1] - The approval for the clinical trial will not have a significant impact on the company's recent performance [1]

由药融圈&Synbio深波联合发起，药融圈产业研究院精心编纂的 《2025中国合成生物制造产业发 展白皮书》 （以下简称《研究报告》），已于8月1日 在Synbio China 第三届中国合成生物学"科 学家+企业家+投资家"博览会正式发布！ 本白皮书介绍了生物制造的发展现状及趋势，分析了生物制造的产业链和重点应用方向， 并精选 出中国生物制造产业10大链主企业，整理了15家上市公司合成生物学布局方向以及20大热门品种 ，同时探讨了生物制造面临的挑战，最终提出了针对性的政策建议，供业内参考 。 领取方式： 关注本公众号，扫码添加下方微信获取 添加请备注：单位+职位+姓名 封面一览 Synthetic Biology 深波 1 251 息息与人脉精准链接平台 2025中国合成生物 制造产业发展白皮书 近年来，生物制造的热度居高不下，作为新兴的战略性领域，生物制造因其创新性和对传 统生产方式的颠覆性，被视为新的增长点，有助于推动产业结构优化和经济模式的转变。 China's synthetic biomanufacturing industry Development White Paper 目录 一、 凯赛生物 ...